S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NASDAQ:CRMDCorMedix Stock Price, Forecast & News

$5.88
-0.26 (-4.23 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.88
Now: $5.88
$6.18
50-Day Range
$4.38
MA: $5.71
$6.56
52-Week Range
$2.16
Now: $5.88
$9.93
Volume283,100 shs
Average Volume259,187 shs
Market Capitalization$153.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRMD
CUSIPN/A
Phone908-517-9500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$153.63 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

CorMedix (NASDAQ:CRMD) Frequently Asked Questions

How has CorMedix's stock been impacted by COVID-19 (Coronavirus)?

CorMedix's stock was trading at $5.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRMD stock has increased by 17.1% and is now trading at $5.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CorMedix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CorMedix.

When is CorMedix's next earnings date?

CorMedix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for CorMedix.

How were CorMedix's earnings last quarter?

CorMedix Inc (NASDAQ:CRMD) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.02. The firm earned $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. View CorMedix's earnings history.

Has CorMedix been receiving favorable news coverage?

News articles about CRMD stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CorMedix earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about CorMedix.

Who are some of CorMedix's key competitors?

What other stocks do shareholders of CorMedix own?

Who are CorMedix's key executives?

CorMedix's management team includes the following people:
  • Mr. Khoso Baluch, CEO & Director (Age 60)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 62)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)
  • Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance

What is CorMedix's stock symbol?

CorMedix trades on the NASDAQ under the ticker symbol "CRMD."

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $5.88.

How big of a company is CorMedix?

CorMedix has a market capitalization of $153.63 million.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

How can I contact CorMedix?

The company can be reached via phone at 908-517-9500.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.